The calculation workspace
GLP-1 Dose Conversion & Switching Reference
Pick any GLP-1 compound, method (injection or oral), dosing period, and mg amount to compare aligned dose ladders or adjust schedules.
Approved transitions follow DailyMed prescribing labels; cross-compound, custom-period, and investigational retatrutide values are rough estimates anchored to reference brands and trials. Your prescriber decides how to switch.
1. Compare GLP-1 Doses & Schedules
Current
Switching to
Smallest doses at top; lower down = stronger estimated steady-state effect. Reference rungs sit at standard cadence; custom doses or periods show as diamonds. Tap any rung on the left to fill that dose.
2. GLP-1 Reference Ladders by Compound & Method
Approved ladders come from DailyMed Section 2 at standard cadence. Retatrutide is investigational (not FDA-approved) and lists Phase 3 TRIUMPH-1 steps for orientation only.
| Compound & method | Reference brands / status | Start | Maintenance / trial | Max |
|---|---|---|---|---|
| Semaglutide · Injection | Ozempic (0.25–2 mg/wk), Wegovy (0.25–7.2 mg/wk) | 0.25 mg / wk | 0.5 / 1 / 1.7 / 2 / 2.4 / 7.2 mg | 7.2 mg / wk |
| Semaglutide · Oral | Ozempic tablets (1.5–9 mg/d), Wegovy tablets (1.5–25 mg/d); legacy Rybelsus 3/7/14 mg ≈ 1.5/4/9 mg | 1.5 mg / day | 4 / 9 / 25 mg | 25 mg / day |
| Tirzepatide · Injection | Mounjaro, Zepbound | 2.5 mg / wk | 5 / 10 / 15 mg | 15 mg / wk |
| Retatrutide · Injection (investigational) | Not FDA approved (Phase 3 TRIUMPH-1) | 2 mg / wk | 4 / 9 / 12 mg (trial) | 12 mg (trial) / wk |
| Orforglipron · Oral | Foundayo | 0.8 mg / day | 5.5 / 9 / 17.2 mg | 17.2 mg / day |
Sources — DailyMed labels: Ozempic, Wegovy, Rybelsus / Ozempic tablets, Mounjaro, Zepbound, Foundayo; investigational retatrutide: TRIUMPH-1 (NEJM 2026).
4. GLP-1 Dose Conversion FAQ
Is there an official conversion chart between semaglutide, tirzepatide, and retatrutide?
No. They are different molecules with distinct receptor profiles, and retatrutide is investigational with no approved label. No FDA label publishes a cross-molecule mg conversion chart.
Which switches have explicit FDA label rules?
At standard dosing periods, FDA labels document semaglutide injection ↔ oral transitions: Ozempic 0.5 mg/wk → Ozempic tablets 4 or 9 mg/d (legacy Rybelsus 7 or 14 mg/d), and Wegovy 2.4 mg/wk ↔ Wegovy 25 mg/d.
How does changing the dosing period work?
When you pick a non-standard interval (such as twice a week or every 5 days), the tool scales by average steady-state dose rate per standard period. Shorter intervals reduce peak-to-trough swings while longer ones widen them; check half-life limits with your prescriber.
Can you overlap two GLP-1 compounds when switching?
No. All approved labels state not to combine GLP-1 receptor agonists. Your prescriber sets the gap and starting step based on half-life and tolerability.
How are the estimated conversions calculated?
Each compound is placed on a shared semaglutide-injection-equivalent scale using FDA label and published trial outcomes: Zepbound 5/10/15 mg (−15.0/−19.5/−20.9%) vs Wegovy 2.4/7.2 mg (−14.9/−18.8%), TRIUMPH-1 retatrutide (4/9/12 mg: −17.6/−23.7/−25.0%), and Foundayo 17.2 mg (−11.1%).